Hepatoblastoma is the most common pediatric liver malignancy, typically striking children
within the first 3 years of their young lives. While advances in chemotherapy and newer …

The most frequent liver tumor in children is hepatoblastoma (HB), which derives from
embryonic parenchymal liver cells or hepatoblasts. Hepatocellular carcinoma (HCC), which …

Tyrosine kinase inhibitors (TKIs) have revolutionized the prognosis of chronic myeloid
leukemia. With the advent of highly efficacious therapy, the focus has shifted toward …

Purpose The objective of this study was to evaluate the response rate, survival, and adverse
effects of hepatic arterial infusion chemotherapy (HAIC) using cisplatin in patients with …

Approximately 20% of children with hepatoblastoma (HB) have metastatic disease at
diagnosis, most frequently in the lungs. In children with HB, lung metastatic disease is …

Precision medicine incorporates the unique genetic alterations of a patient's disease to
guide their therapy. One of the earliest well-known examples of precision medicine in the …

Limited research exists regarding the most aggressive forms of hepatoblastoma. Cell lines of
the rare subtypes of hepatoblastoma with poor prognosis are not only difficult to attain but …

Hepatoblastoma is a malignant embryonal tumor with multiple differentiation modes and is
the clearest liver malignancy in children. However, little is known about genetic and …

Aim Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death
worldwide. Systemic chemotherapy such as cisplatin and multi-targeted receptor tyrosine …

Drug resistance in cancer, still poses therapeutic challenges and tumor microenvironment
plays a critical role in it. Microvesicles (MVs) are effective transporters of the molecular …